UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Extramedullary Plasmacytoma Mimicking Gallbladder Cancer

Internal Medicine, 2023/09/01, Vol.62(17), pp.2581-2582

2023

Volltextzugriff (PDF)

The clonal evolution during long-term clinical course of multiple myeloma

International journal of hematology, 2021-02, Vol.113 (2), p.279-284

2021

Volltextzugriff (PDF)

Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy

Scientific reports, 2023-08, Vol.13 (1), p.13713-13713, Article 13713

2023

Volltextzugriff (PDF)

Serum cell-free DNA concentration as a possible prognostic marker in newly diagnosed diffuse large B-cell lymphoma

Biomedical Research, 2022/08/18, Vol.43(4), pp.99-106

2022

Volltextzugriff (PDF)

Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma

Journal of Clinical and Experimental Hematopathology, 2024, Vol.64(1), pp.10-20

2024

Volltextzugriff (PDF)

Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study

International journal of hematology, 2020-04, Vol.111 (4), p.567-573

2020

Volltextzugriff (PDF)

Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents

Cancer medicine (Malden, MA), 2024-08, Vol.13 (16), p.e70128-n/a

2024

Volltextzugriff (PDF)

Recent advances and future perspectives of T-cell engagers in lymphoid malignancies

Japanese journal of clinical oncology, 2024-04, Vol.54 (4), p.376-385

2024

Volltextzugriff (PDF)

PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A SINGLE‐INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES

HemaSphere, 2023-08, Vol.7 (S3), p.e3121335-n/a

2023

Volltextzugriff (PDF)

P1106: CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY GASTRIC MUCOSA‐ASSOCIATED LYMPHOID TISSUE LYMPHOMA: LONG‐TERM FOLLOW‐UP RESULTS FROM A SINGLE‐INSTITUTION OBSERVATIONAL STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e64794e6-n/a

2023

Volltextzugriff (PDF)

Diffuse large B‐cell lymphoma arising immediately after completion of treatment for Hodgkin lymphoma

EJHaem, 2021-11, Vol.2 (4), p.883-884

2021

Volltextzugriff (PDF)

P33-7 Two patients with DLBCL who developed aortitis following pegfilgrastim administration during chemoimmunotherapy

Annals of oncology, 2023-11, Vol.34, p.S1454-S1454

2023

Volltextzugriff (PDF)

The Seven-Color FISH Analysis Can Detect the Acquisition Pattern of Complex Chromosomal Abnormalities Related to Poor Response and Prognosis in Patients with Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.6624-6624

2023

Volltextzugriff (PDF)

P-312 Impact of the IF system using HYDRASHIFTon response evaluation for patients under treatment with the IgG-κ monoclonal antibody, Isatuximab

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S210-S210

2023

Volltextzugriff (PDF)

P-128: Accompanying with additional complex karyotype is a poor prognostic factor in patients with multiple myeloma with high-risk cytogenetics in the era of novel agents

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S105-S105

2021

Volltextzugriff (PDF)

Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population

Leukemia & lymphoma, 2021-07, Vol.62 (8), p.1869-1876

2021

Volltextzugriff (PDF)

Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma

Journal of Clinical and Experimental Hematopathology, 2024, Vol.64 (1), p.10-20

2024

Volltextzugriff (PDF)

Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma

Leukemia & lymphoma, 2021-07, Vol.62 (9), p.2141-2150

2021

Volltextzugriff (PDF)

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Blood, 2019-11, Vol.134 (Supplement_1), p.1498-1498

2019

Volltextzugriff (PDF)

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Blood, 2019-11, Vol.134 (Supplement_1), p.5515-5515

2019

Volltextzugriff (PDF)

Cell-Free DNA Genotyping Analysis in Diffuse Large B-Cell Lymphoma; The Correlation between TP53 Gene Mutation and Cereblon Gene Mutation

Blood, 2019-11, Vol.134 (Supplement_1), p.2786-2786

2019

Volltextzugriff (PDF)

Impact of Mogamulizumab-Containing Chemotherapy on HBV Reactivation in Patients with T-Cell Lymphoma: A Multicenter Retrospective Observational Study (PROACTIVE-MOGA)

Blood, 2023-11, Vol.142 (Supplement 1), p.6192-6192

2023

Volltextzugriff (PDF)

The Prognosis of Transformed DLBCL Were Superior to De Novo DLBL after the Relapsed/Refractory Status Related to the MYC Translocation

Blood, 2018-11, Vol.132 (Supplement 1), p.5417-5417

2018

Volltextzugriff (PDF)

Impact of Creatinine Clearance in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP : A Real-World Long-Term Observation Analysis at a Single Institute

Blood, 2018-11, Vol.132 (Supplement 1), p.5399-5399

2018

Volltextzugriff (PDF)

Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation

Blood, 2018-11, Vol.132 (Supplement 1), p.4229-4229

2018

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(29)

Sprache

Englisch
(28)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(10)
Life Sciences & Biomedicine
(9)
Oncology
(6)
Hematology
(5)
Multiple Myeloma
(5)
Chemotherapy
(4)
Lymphoma
(4)
B-Cell Lymphoma
(3)
Humans
(3)
Lymphocytes B
(3)
Medical Prognosis
(3)
Survival
(3)
Antibodies, Monoclonal - Therapeutic Use
(2)
Cancer
(2)
Dlbcl
(2)
Medicine
(2)
Medicine & Public Health
(2)
Monoclonal Antibodies
(2)
Multiple Myeloma - Drug Therapy
(2)
Patients
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Extramedullary Plasmacytoma Mimicking Gallbladder Cancer

The clonal evolution during long-term clinical course of multiple myeloma

Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy

Serum cell-free DNA concentration as a possible prognostic marker in newly diagnosed diffuse large B-cell lymphoma

Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma

Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study

Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents

Recent advances and future perspectives of T-cell engagers in lymphoid malignancies

PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A SINGLE‐INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES

P1106: CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY GASTRIC MUCOSA‐ASSOCIATED LYMPHOID TISSUE LYMPHOMA: LONG‐TERM FOLLOW‐UP RESULTS FROM A SINGLE‐INSTITUTION OBSERVATIONAL STUDY

Diffuse large B‐cell lymphoma arising immediately after completion of treatment for Hodgkin lymphoma

P33-7 Two patients with DLBCL who developed aortitis following pegfilgrastim administration during chemoimmunotherapy

The Seven-Color FISH Analysis Can Detect the Acquisition Pattern of Complex Chromosomal Abnormalities Related to Poor Response and Prognosis in Patients with Multiple Myeloma

P-312 Impact of the IF system using HYDRASHIFTon response evaluation for patients under treatment with the IgG-κ monoclonal antibody, Isatuximab

P-128: Accompanying with additional complex karyotype is a poor prognostic factor in patients with multiple myeloma with high-risk cytogenetics in the era of novel agents

Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population

Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma

Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Cell-Free DNA Genotyping Analysis in Diffuse Large B-Cell Lymphoma; The Correlation between TP53 Gene Mutation and Cereblon Gene Mutation

Impact of Mogamulizumab-Containing Chemotherapy on HBV Reactivation in Patients with T-Cell Lymphoma: A Multicenter Retrospective Observational Study (PROACTIVE-MOGA)

The Prognosis of Transformed DLBCL Were Superior to De Novo DLBL after the Relapsed/Refractory Status Related to the MYC Translocation

Impact of Creatinine Clearance in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP : A Real-World Long-Term Observation Analysis at a Single Institute

Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation

Suchergebnisse filtern